Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluación de la eficacia y la seguridad de belantamab mafodotina, bortezomib y dexametasona frente a daratumumab, bortezomib y dexametasona en participantes con mieloma múltiple en recaída o refractario (DREAMM 7)

29 de octubre de 2026 actualizado por: GlaxoSmithKline

DREAMM 7: Un estudio multicéntrico, abierto, aleatorizado de fase III para evaluar la eficacia y seguridad de la combinación de belantamab mafodotina, bortezomib y dexametasona (B-Vd) en comparación con la combinación de daratumumab, bortezomib y dexametasona (D-Vd ) en participantes con mieloma múltiple en recaída/refractario

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

494

Fase

  • Fase 3

Acceso ampliado

Aprobado en venta al público. Ver registro de acceso ampliado.

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Cologne, Alemania, 50937
        • GSK Investigational Site
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Alemania, 89081
        • GSK Investigational Site
    • Bavaria
      • München, Bavaria, Alemania, 81377
        • GSK Investigational Site
      • Würzburg, Bavaria, Alemania, 97080
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Alemania, 40225
        • GSK Investigational Site
    • Thuringia
      • Jena, Thuringia, Alemania, 07747
        • GSK Investigational Site
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • GSK Investigational Site
      • Liverpool, New South Wales, Australia, 2170
        • GSK Investigational Site
      • Newcastle, New South Wales, Australia, 2298
        • GSK Investigational Site
      • St Leonards, New South Wales, Australia, 2065
        • GSK Investigational Site
      • Wollongong, New South Wales, Australia, 2500
        • GSK Investigational Site
    • Queensland
      • Benowa, Queensland, Australia, 4217
        • GSK Investigational Site
      • Herston, Queensland, Australia, 4029
        • GSK Investigational Site
    • South Australia
      • Ashford, South Australia, Australia, 5037
        • GSK Investigational Site
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • GSK Investigational Site
      • Heidelberg, Victoria, Australia, 3084
        • GSK Investigational Site
      • Melbourne, Victoria, Australia, 3004
        • GSK Investigational Site
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • GSK Investigational Site
      • Nedlands, Western Australia, Australia, 6009
        • GSK Investigational Site
      • Joinville, Brasil, 89201-260
        • GSK Investigational Site
      • Natal, Brasil, 59075-740
        • GSK Investigational Site
      • Rio de Janeiro, Brasil, 22775001
        • GSK Investigational Site
      • São Paulo, Brasil, 04537-080
        • GSK Investigational Site
      • São Paulo, Brasil, 05403-000
        • GSK Investigational Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
        • GSK Investigational Site
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brasil, 88020-210
        • GSK Investigational Site
      • Roeselare, Bélgica, 8800
        • GSK Investigational Site
    • Brussels Capital
      • Jette, Brussels Capital, Bélgica, 1090
        • GSK Investigational Site
      • Woluwé-Saint-Lambert, Brussels Capital, Bélgica, 1200
        • GSK Investigational Site
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, Bélgica, 9000
        • GSK Investigational Site
    • Alberta
      • Edmonton, Alberta, Canadá, T6G 1Z2
        • GSK Investigational Site
    • Ontario
      • London, Ontario, Canadá, N6A 5W9
        • GSK Investigational Site
      • Toronto, Ontario, Canadá, M4N 3M5
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Canadá, H4J 1C5
        • GSK Investigational Site
      • Brno, Chequia, 625 00
        • GSK Investigational Site
      • Hradec Králové, Chequia, 500 05
        • GSK Investigational Site
      • Ostrava, Chequia, 708 52
        • GSK Investigational Site
      • Prague, Chequia, 128 08
        • GSK Investigational Site
      • Pusan, Corea del Sur, 49241
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do, Corea del Sur, 13620
        • GSK Investigational Site
      • Seoul, Corea del Sur, 06351
        • GSK Investigational Site
      • Seoul, Corea del Sur, 06591
        • GSK Investigational Site
      • Ulsan, Corea del Sur, 44033
        • GSK Investigational Site
      • Barcelona, España, 08035
        • GSK Investigational Site
      • Barcelona, España, 08916
        • GSK Investigational Site
      • Cáceres, España, 10003
        • GSK Investigational Site
      • Gijón, España, 33394
        • GSK Investigational Site
      • L'Hospitalet de Llobrega, España, 08908
        • GSK Investigational Site
      • MOstoles Madrid, España, 28933
        • GSK Investigational Site
      • Madrid, España, 28007
        • GSK Investigational Site
      • Madrid, España, 31008
        • GSK Investigational Site
      • Murcia, España, 30008
        • GSK Investigational Site
      • PamplonaNavarra, España, 31008
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, España, 28223
        • GSK Investigational Site
      • Salamanca, España, 37007
        • GSK Investigational Site
    • Arizona
      • Yuma, Arizona, Estados Unidos, 85364
        • GSK Investigational Site
    • Kansas
      • Mission, Kansas, Estados Unidos, 66205-2005
        • GSK Investigational Site
    • North Carolina
      • Denver, North Carolina, Estados Unidos, 80128
        • GSK Investigational Site
    • Ohio
      • Blue Ash, Ohio, Estados Unidos, 45242-5665
        • GSK Investigational Site
    • Texas
      • Tyler, Texas, Estados Unidos, 75702
        • GSK Investigational Site
    • Virginia
      • Roanoke, Virginia, Estados Unidos, 24014
        • GSK Investigational Site
      • Amiens, Francia, 80054
        • GSK Investigational Site
      • Caen, Francia, 14033
        • GSK Investigational Site
      • Nice, Francia, 06200
        • GSK Investigational Site
      • Paris, Francia, 75651
        • GSK Investigational Site
      • Rennes, Francia, 35033
        • GSK Investigational Site
      • Athens, Grecia, 11528
        • GSK Investigational Site
      • Thessaloniki, Grecia, 54007
        • GSK Investigational Site
    • East Macedonia and Thrace
      • Alexandroupoli, East Macedonia and Thrace, Grecia, 681 00
        • GSK Investigational Site
      • Jerusalem, Israel, 91120
        • GSK Investigational Site
      • Kfar Saba, Israel, 44281
        • GSK Investigational Site
      • Ramat Gan, Israel, 52621
        • GSK Investigational Site
      • Tel Aviv, Israel, 64239
        • GSK Investigational Site
      • Bergamo, Italia, 24127
        • GSK Investigational Site
      • Bologna, Italia, 40138
        • GSK Investigational Site
      • Brescia, Italia, 25123
        • GSK Investigational Site
      • Catania, Italia, 95123
        • GSK Investigational Site
      • Meldola FC, Italia, 47014
        • GSK Investigational Site
      • Milan, Italia, 20133
        • GSK Investigational Site
      • Ravenna, Italia, 48121
        • GSK Investigational Site
      • Roma, Italia, 00168
        • GSK Investigational Site
      • Siena, Italia, 53100
        • GSK Investigational Site
      • Torino, Italia, 10126
        • GSK Investigational Site
      • Aichi, Japón, 467-8602
        • GSK Investigational Site
      • Aichi, Japón, 441-8570
        • GSK Investigational Site
      • Aomori, Japón, 030-8553
        • GSK Investigational Site
      • Ehime, Japón, 790-8524
        • GSK Investigational Site
      • Fukuoka, Japón, 806-8501
        • GSK Investigational Site
      • Fukuoka, Japón, 807-8555
        • GSK Investigational Site
      • Fukuoka, Japón, 810-8563
        • GSK Investigational Site
      • Fukuoka, Japón, 815-8555
        • GSK Investigational Site
      • Gifu, Japón, 503-8502
        • GSK Investigational Site
      • Gunma, Japón, 377-0280
        • GSK Investigational Site
      • Hyōgo, Japón, 670-8540
        • GSK Investigational Site
      • Kanagawa, Japón, 247-8533
        • GSK Investigational Site
      • Kanagawa, Japón, 221-0855
        • GSK Investigational Site
      • Kochi, Japón, 781-8555
        • GSK Investigational Site
      • Nagano, Japón, 392-8510
        • GSK Investigational Site
      • Okayama, Japón, 701-1192
        • GSK Investigational Site
      • Osaka, Japón, 545-8586
        • GSK Investigational Site
      • Osaka, Japón, 530-0012
        • GSK Investigational Site
      • Shizuoka, Japón, 411-8777
        • GSK Investigational Site
      • Christchurch, Nueva Zelanda, 8011
        • GSK Investigational Site
      • Dunedin, Nueva Zelanda, 9054
        • GSK Investigational Site
      • Takapuna Auckland, Nueva Zelanda, 1309
        • GSK Investigational Site
      • Wellington, Nueva Zelanda, 6021
        • GSK Investigational Site
      • Groningen, Países Bajos, 9713 GZ
        • GSK Investigational Site
    • South Holland
      • Dordrecht, South Holland, Países Bajos, 3318 AT
        • GSK Investigational Site
      • Chorzów, Polonia, 41-500
        • GSK Investigational Site
      • Krakow, Polonia, 30510
        • GSK Investigational Site
      • Lodz, Polonia, 93-513
        • GSK Investigational Site
      • Lublin, Polonia, 20-081
        • GSK Investigational Site
      • Lublin, Polonia, 20-090
        • GSK Investigational Site
      • Nowy Sącz, Polonia, 33-300
        • GSK Investigational Site
      • Poznan, Polonia, 60-569
        • GSK Investigational Site
      • Warsaw, Polonia, 02-781
        • GSK Investigational Site
      • Beijing, Porcelana, 100191
        • GSK Investigational Site
      • Beijing, Porcelana, 100020
        • GSK Investigational Site
      • Changchun, Porcelana, 130012
        • GSK Investigational Site
      • Guangzhou, Porcelana, 510060
        • GSK Investigational Site
      • Guangzhou, Porcelana, 510515
        • GSK Investigational Site
      • Hangzhou, Porcelana, 310003
        • GSK Investigational Site
      • Jinan, Porcelana, 250012
        • GSK Investigational Site
      • Nanjing, Porcelana, 210008
        • GSK Investigational Site
      • Shenyang, Porcelana, 110001
        • GSK Investigational Site
      • Suzhou, Porcelana, 215006
        • GSK Investigational Site
      • Tianjin, Porcelana, 300020
        • GSK Investigational Site
      • Zhengzhou, Porcelana, 450052
        • GSK Investigational Site
      • Bournemouth, Reino Unido, BH7 7DW
        • GSK Investigational Site
      • Cardiff, Reino Unido, CF14 4XW
        • GSK Investigational Site
      • Dundee, Reino Unido, DD1 9SY
        • GSK Investigational Site
      • Leicester, Reino Unido, LE1 5WW
        • GSK Investigational Site
      • London, Reino Unido, W12 0NN
        • GSK Investigational Site
      • Stoke-on-Trent, Reino Unido, ST4 6QG
        • GSK Investigational Site
      • Sutton, Reino Unido, SM2 5PT
        • GSK Investigational Site
      • Moscow, Rusia, 125284
        • GSK Investigational Site
      • Nizhny Novgorod, Rusia, 603126
        • GSK Investigational Site
      • Novosibirsk, Rusia, 630087
        • GSK Investigational Site
      • Saint Petersburg, Rusia, 191024
        • GSK Investigational Site
      • Saint Petersburg, Rusia, 197 089
        • GSK Investigational Site
      • Samara, Rusia, 443021
        • GSK Investigational Site
      • Saratov, Rusia, 410028
        • GSK Investigational Site
      • Ufa, Rusia, 450083
        • GSK Investigational Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.

  • Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Must have at least 1 aspect of measurable disease, defined as one of the following;

    1. Urine M-protein excretion >=200 mg per 24-hour, or
    2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
    3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
  • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.

  • Adequate organ function

Exclusion Criteria:

  • Intolerant to daratumumab.
  • Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
  • Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
  • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
  • Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
  • Prior allogenic stem cell transplant.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
  • Corneal epithelial disease.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Belantamab mafodotina y bortezomib más dexametasona (Brazo A)

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Comparador activo: Daratumumab y Bortezomib más Dexametasona (Brazo B)

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Anti-cluster of differentiation 38 [CD-38] monoclonal antibody

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression-free Survival (PFS)
Periodo de tiempo: Up to approximately 41 months

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis.

Up to approximately 41 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Número de participantes con hallazgos oculares anormales en el examen oftálmico
Periodo de tiempo: Hasta 73 meses
Hasta 73 meses
Complete Response Rate (CRR)
Periodo de tiempo: Up to 73 months

CRR is defined as percentage of participants with a confirmed complete response or better.

Up to 73 months
Overall Response Rate (ORR)
Periodo de tiempo: Up to 73 months

ORR is defined as percentage of participants with a confirmed partial response or better.

Up to 73 months
Clinical Benefit Rate (CBR)
Periodo de tiempo: Up to 73 months

CBR is defined as percentage of participants with a confirmed minimal response (MR) or better

Up to 73 months
Duration of Response (DoR)
Periodo de tiempo: Up to 73 months

DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

Up to 73 months
Time to Response (TTR)
Periodo de tiempo: Up to 73 months

TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

Up to 73 months
Time to Progression (TTP)
Periodo de tiempo: Up to 73 months

TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.

Up to 73 months
Overall Survival (OS)
Periodo de tiempo: Up to 73 months

OS is defined as time from the date of randomization until the date of death due to any cause.

Up to 73 months
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Periodo de tiempo: Up to 73 months

Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

Up to 73 months
Minimal Residual Disease (MRD) Negativity Rate
Periodo de tiempo: Up to 73 months

Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS).

Up to 73 months
Number of Participants With Adverse Events (AEs)
Periodo de tiempo: Up to 73 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Up to 73 months
Number of Participants With Clinically Significant Changes in Hematology Parameters
Periodo de tiempo: Up to 73 months

Blood samples will be collected for the analysis of hematology parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Periodo de tiempo: Up to 73 months

Blood samples will be collected for the analysis of clinical chemistry parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Urine Dipstick
Periodo de tiempo: Up to 73 months

Urine samples will be collected for the urine dipstick analysis.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Periodo de tiempo: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Periodo de tiempo: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Periodo de tiempo: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Periodo de tiempo: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

Up to 73 months
Titers of ADAs Against Belantamab Mafodotin
Periodo de tiempo: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers.

Up to 73 months
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Periodo de tiempo: Up to 73 months

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Up to 73 months
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Periodo de tiempo: Up to 73 months

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Up to 73 months
Change From Baseline in HRQoL as Measured by EORTC IL52
Periodo de tiempo: Up to 73 months

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning.

Up to 73 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: GSK Clinical Trials, GlaxoSmithKline

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

7 de mayo de 2020

Finalización primaria (Actual)

2 de octubre de 2023

Finalización del estudio (Estimado)

8 de octubre de 2029

Fechas de registro del estudio

Enviado por primera vez

27 de enero de 2020

Primero enviado que cumplió con los criterios de control de calidad

27 de enero de 2020

Publicado por primera vez (Actual)

29 de enero de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir